Integrative polygenic risk score improves the prediction accuracy of complex traits and diseases

Buu Truong[1,2], Leland E. Hull[3,4], Yunfeng Ruan[1,2], Qin Qin Huang[5], Whitney Hornsby[1,2], Hilary Martin[5], David A. van Heel[6], Ying Wang[1,7,8], Alicia R. Martin[7,8], S. Hong Lee[9], Pradeep Natarajan[1,2,4]

[1]Program in Medical and Population Genetics and the Cardiovascular Disease Initiative, Broad Institute of MIT and Harvard, 415 Main St, Cambridge, MA 02142
[2]Center for Genomic Medicine and Cardiovascular Research Center, Massachusetts General Hospital, 185 Cambridge Street, Boston, MA, 02114
[3]Division of General Internal Medicine, 100 Cambridge Street, Massachusetts General Hospital, Boston, MA, 02114
[4]Department of Medicine, Harvard Medical School, 25 Shattuck Street, Boston, MA 02115
[5]Department of Human Genetics, Wellcome Sanger Institute, Cambridge, UK
[6]Blizard Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, UK
[7]Stanley Center for Psychiatric Research, Broad Institute of Harvard and MIT, Cambridge, MA, USA
[8]Analytic and Translational Genetics Unit, Massachusetts General Hospital, Boston, MA, USA
[9]Australian Centre for Precision Health, University of South Australia Cancer Research Institute, University of South Australia, Adelaide, SA, 5000, Australia

Please address correspondence to:
    Pradeep Natarajan, MD MMSc
    185 Cambridge Street, CPZN 3.184, Boston, MA 02114
    pnatarajan@mgh.harvard.edu
    617-726-1843

ABSTRACT

Polygenic risk scores (PRS) are an emerging tool to predict the clinical phenotypes and outcomes of individuals. Validation and transferability of existing PRS across independent datasets and diverse ancestries are limited, which hinders the practical utility and exacerbates health disparities. We propose PRSmix, a framework that evaluates and leverages the PRS corpus of a target trait to improve prediction accuracy, and PRSmix+, which incorporates genetically correlated traits to better capture the human genetic architecture. We applied PRSmix to 47 and 32 diseases/traits in European and South Asian ancestries, respectively. PRSmix demonstrated a mean prediction accuracy improvement of 1.23-fold (95% CI: [1.18; 1.29]; P-value < 2×10^{-16}) and 1.19-fold (95% CI: [1.11; 1.27]; P-value = 3.94×10^{-6}), and PRSmix+ improved the prediction accuracy by 1.71-fold (95% CI: [1.48; 1.94]; P-value = 9.98×10^{-10}) and 1.41-fold (95% CI: [1.24; 1.58]; P-value = 2.51×10^{-6}) in European and South Asian ancestries, respectively. Our method provides a comprehensive framework to benchmark and leverage the combined power of PRS for maximal performance in a desired target population.

INTRODUCTION

Thousands of polygenic risk scores (PRS) have been developed to predict an individual's genetic propensity to diverse phenotypes[1]. PRS are generated when risk alleles for distinct phenotypes are weighted by their effect size estimates and summed[2]. Risk alleles included in PRS have traditionally been identified from genome-wide association studies (GWAS) results conducted on a training dataset, which are weighted and aggregated to derive a PRS to predict distinct phenotypes. The association between PRS and the phenotype of interest is subsequently evaluated in a test dataset that is non-overlapping with the training dataset[3].

Most PRS have been developed in specific cohorts that may vary in terms of population demographics, admixture, environment, and SNP availability. Limited validation of many PRS outside of the training datasets and poor transferability of PRS to other populations may limit their clinical utility. However, pooling of data from individual PRS generated and validated in diverse cohorts has the potential to improve the predictive ability of PRS across diverse populations. The Polygenic Score Catalog (PGS Catalog) is a publicly available repository that archives SNP effect sizes for PRS estimation. The SNP effect sizes were developed from various methods (e.g. P+T[4], LDpred[5,6], PRS-CS[7], etc.) to obtain the highest prediction accuracy in the studied dataset. PRS metadata enables researchers to replicate PRS in independent cohorts and aggregate SNP effects to refine PRS and enhance the accuracy and generalizability in broader populations[8]. However, optimizing PRS performance requires methodological approaches to adjust GWAS estimate effect sizes that take into account correlated SNPs (i.e., linkage disequilibrium) and refine PRS for the target population[4,5,7,9–12]. Furthermore, numerous scores are often present for single traits with varied validation metrics in non-overlapping cohorts. There is a lack of standardized approaches combining PRS from this growing corpus to enhance prediction accuracy and generalizability while minimizing bias, for a target cohort[8,11,13].

To address these issues, we sought to: 1) validate previously developed PRS in two geographically and ancestrally distinct cohorts, the *All of Us* Research Program (AoU) and the Genes & Health cohort, and 2) present and evaluate new methods for combining previously calculated PRS to maximize performance beyond all best performing published PRS. To better capture the genetic architecture of the outcome traits, we proposed PRSmix, a framework to combine PRS from the same trait with the outcome trait. Previous studies highlighted the effect of pleiotropic information on a trait's genetic architecture[14,15]. Therefore, we proposed PRSmix+ to additionally combine PRS from other genetically correlated traits to further improve the PRS for a given trait.

To assess the prediction improvement, we performed PRSmix and PRSmix+ for 47 traits in European ancestry and 32 traits in South Asian ancestry. We evaluated 1) the relative improvement of the proposed framework over the best-performing pre-existing PRS for each trait, 2) the efficient training sample sizes required to improve the PRS, 3) the predictive improvement in 6 groups including anthropometrics, blood counts, cancer, cardiometabolic, biochemistry and other conditions as the prediction accuracies varied in each group, and 4) the clinical utility and pleiotropic effect of the newly built PRS for coronary artery disease. Overall, we show that PRSmix and PRSmix+ significantly improved prediction accuracy. An R package for preprocessing and harmonizing the SNP effects from the PGS Catalog as well as assessing and combining the scores was developed to facilitate the combining of

97 pre-existing PRS scores for both ancestry-specific and cross-ancestry contexts using the
98 totality of published PRS. The development of this framework has the potential to improve
99 precision health by improving the generalizability in the application of PRS[16].
100
101 **RESULTS**
102
103 **Overview of methods**
104
105

106
Figure 1. The framework of the trait-specific and cross-trait PRS integration. In Phase
1, we obtained the SNP effects from the PGS Catalog and then harmonized the effect alleles
as the alternative alleles in the independent cohorts. In each independent biobank (*All of Us*,
Genes & Health), we estimated the PRS and split the data into training (80%) and testing
(20%) datasets. In Phase 2, in the training dataset, we trained the Elastic Net model with
high-power scores to estimate the mixing weights for the PRSs. The training phase could
include PRSs from traits corresponding to outcomes (PRSmix) or all traits (PRSmix+). The
training was adjusted for age, sex, and 10 principal components (PCs). In Phase 3, we
adjusted the per-allele effect sizes from each single PRS by multiplying with the
corresponding mixing weights obtained in the training phase. The final per-allele effect sizes
are estimated as the weighted sum of the SNP effects across different single scores. In
Phase 4, we evaluated the re-estimated per-allele effect sizes in the testing dataset.
119
120 A single PRS may only reflect genetic effects captured in the discovery dataset of a single
121 study that may be only a part of the total genetic effects underlying the trait of interest.
122 Therefore, we harmonized and combined multiple sets of PRS to establish a new set of
123 scores, which gather information across studies and traits. Our approach leveraged multiple
124 well-powered PRSs to improve prediction accuracy and is detailed in Fig. 1.
125
Our combination frameworks leveraged the PGS Catalog[17] as the resource of SNP effects to
estimate single PRSs. To avoid overfitting, we used *All of Us* and Genes & Health cohorts
(see Methods) due to non-overlapping samples from the original GWAS. We randomly
divided the target cohort into a training set (80%) and a testing set (20%). We selected the

most common traits from the PGS Catalog which have the highest number of PRS. For the
stability of the linear combination, we curated binary traits with a prevalence > 2% in the
target cohort. Continuous traits were assessed using partial R^2 which is estimated as the
difference between the full model of PRS and covariates (age, sex, and 10 PCs) and the null
model of only covariates. For binary traits, the prediction accuracy was converted to liability
R^2 with disease prevalence approximated as the prevalence in the corresponding cohort.
136
To combine the scores, we employed Elastic Net[18] to construct linear combinations of the
PRS. We proposed two combination frameworks: 1) PRSmix combines the scores
developed from the same outcome trait, and 2) PRSmix+ combines all the high-power
scores across other traits. Trait-specific combinations, PRSmix, can leverage the PRSs
developed from different studies and methods to more fully capture the genetic effects
underlying the traits. It has also been shown that complex traits are determined by genes
with pleiotropic effects[15]. Therefore, we additionally proposed a cross-trait combination,
PRSmix+, to make use of pleiotropic effects and further improve prediction accuracy.
145
First, we evaluated the improvement for each method, defined as the fold-ratio of the method
compared to the prediction accuracy of the best single PRS. For a fair comparison with the
proposed framework, we selected the best single PRS from the training set and evaluated its
performance in the testing set. First, we performed simulations to assess the improvement
with various heritabilities and training sample sizes. We estimated the slope of improvement
of prediction accuracy by increasing training sample sizes for various heritabilities.
152
Next, we applied the proposed frameworks in two distinct cohorts; (1) the *All of Us* program,
in which 47 traits were tested in U.S. residents of European ancestry, and (2) the Genes &
Health (G&H) cohort, in which 32 traits were tested in British South Asian ancestry
(Supplementary Table 1). In each cohort, we compared the improvement of our proposed
framework with the single best score from the PGS Catalog. We estimated the averaged
fold-ratio as a measure of the improvement of prediction accuracy by our approach,
compared to the best single score from PGS Catalog. We also classified the traits into 6
categories as anthropometrics, blood counts, cancer, cardiometabolic, biochemistry, and
other conditions (Supplementary Table 2 and 3). Cancer traits were not considered in the
younger Genes & Health cohort due to their low prevalence (<2%). We then present
additional detailed analyses for coronary artery disease focused on clinical utility
improvements relative to existing PRS.
165
166 **Simulations were used to evaluate the combination frameworks**
167

Figure 2. Simulations to demonstrate the predictive improvement of PRSmix and PRSmix+. The points and triangles represent the mean fold-ratio of R^2 between **(a)** PRSmix and **(b)** PRSmix+, respectively, versus the best single PRS. **(c)** The improvement per logarithm with base 10 of sample size for various heritabilities was represented as a slope of a linear regression of fold-ratio ~ log10(N). In simulations, the correlation within simulated trait-specific PRSs was 0.8, and the correlation between trait-specific and correlated PRSs was 0.4 (see Methods). The whiskers demonstrate confidence intervals across 200 replications. The dashed red lines represent the reference for fold-ratio equal 1 for (a) and (b), and equal 0 for (c).

To compare the performance of PRSmix and PRSmix+ against the best single PRS and evaluate the sample sizes needed for training the mixing weights, we performed simulations with real genotypes of European ancestry in the UK Biobank given the large sample sizes available (Fig. 2). Briefly, we randomly split 7,000 individuals as a testing data set mimicking the testing size of 20% of real data. In the remaining dataset, we used 200,000 individuals for GWAS to estimate the SNP effect sizes for PRS calculations. Finally, with the rest of the data, we randomly selected different sample sizes as the training sample to evaluate the sample sizes needed to train the mixing weights. To assess the improvement of PRS performance, we computed the fold-ratio of prediction accuracy R^2 between PRSmix and PRSmix+ against the best-performing single simulated PRS.

Our results showed that the trait-specific combination, PRSmix, showed no improvement with the training sample smaller than 500 for most of the traits. Our simulations illustrated that traits with low heritability required a larger sample size to achieve an improvement compared to traits with high heritability (Fig. 2a and 2b). PRSmix demonstrated a better performance compared to the best single PRS with training sample sizes from $N_{training}$ = 200 samples for the high heritable trait (h^2 = 0.4) to $N_{training}$ = 5000 samples for the low heritable trait (h^2=0.05) (Fig. 2a and 2b). We observed that PRSmix demonstrated a saturation of improvement from $N_{training}$ = 10,000. PRSmix+ demonstrated negligible further improvement when the training sample size was increased from 30,000 but maintained consistent improvement relative to PRSmix and the best single PRS. Moreover, we observed that traits with higher heritability or higher best prediction accuracy of a single PRS demonstrated a smaller improvement compared to traits with a smaller heritability (Fig. 2c).

203
204
205 **Combining trait-specific PRS improves prediction accuracy (PRSmix)**
206

207
208
Figure 3. Comparison of PRSmix and PRSmix+ versus the best PGS Catalog in
European and South Asian ancestries. The relative improvement compared to the best
single PRS was assessed in **(a)** the European ancestry in the *All of US* cohort and **(b)** South
Asian ancestry in the Genes & Health cohort. PRSmix combines trait-specific PRSs and
PRSmix+ combines additional PRSs from other traits. The best PGS Catalog score was
selected by the best performance trait-specific score in the training sample and evaluated in
the testing sample. The prediction accuracy (R^2) was calculated as partial R^2 which is a
difference of R^2 between the model with PRS and covariates including age, sex, and 10 PCs
versus the base model with only covariates. Prediction accuracy for binary traits was
assessed with liability-R^2 where disease prevalence was approximately estimated as a
proportion of cases in the testing set. The whiskers reflect the maximum and minimum
values within the 1.5 **×** interquartile range. The bars represent the ratio of prediction
accuracy of PRSmix and PRSmix+ versus the best PRS from the PGS Catalog across 47
traits and 32 traits in *All of Us* and Genes and Heath cohorts, respectively, and the whiskers
demonstrate 95% confidence intervals. P-values for significance difference of the fold-ratio
from 1 using a two-tailed paired t-test. PRS: Polygenic risk scores.
225
To determine if a trait-specific combination, namely PRSmix, would improve the accuracy of
PRS prediction, we used data from European ancestry participants in the *All of Us* research
program who had undergone whole genome sequencing, and Genes & Health participants
of South Asian ancestry. We randomly split the independent cohorts into training (80%) and
testing sets (20%). The training set was used to train the weights of each PRS, referred as
mixing weights, that indicate how much each PRS explain the phenotypic variance in the
training set, and the PRS accuracies were evaluated in the testing set (Fig. 1). We curated
47 traits and 32 traits in the *All of Us* and Genes & Health cohorts, respectively. For binary
traits, we removed traits with a prevalence of smaller than 2% (see Methods, Supplementary
Table 1). Traits with the best-performance trait-specific single PRS which showed a lack of

power were also removed. Overall, we observed a significant improvement compared to 1 using a two-tailed paired t-test with PRSmix. PRSmix significantly improves the prediction accuracy compared to the best PRS estimated from the PGS Catalog. PRSmix improved 1.22-fold (95% CI: [1.17; 1.27]; P-value < 2 x 10^{-16}) and 1.19-fold (95% CI: [1.11; 1.27]; P-value = 1.92 x 10^{-6}) compared to the best PRS from PGS Catalog for European ancestry and South Asian ancestry, respectively.

In European ancestry, we observed the greatest improvement of PRSmix against the best single PRS for rheumatoid arthritis of 1.93-fold. Furthermore, in South Asian ancestry, we observed that PRSmix of coronary artery disease had the best improvement of 2.32-fold compared to the best-performance single PRS. Details of the prediction accuracy are shown in Supplementary Fig. 1, 2 and Supplementary Table 2, 3. This was consistent with findings in simulations since traits with a lower single PRS performance demonstrated a better improvement with the combination strategy.

Cross-trait combination further improved PRS accuracy and highlighted the contribution of pleiotropic effects

We next assessed the contribution of pleiotropic effects from cross-trait PRSs to determine if these would further improve the combination framework (PRSmix+), by including high-power PRSs from within 2600 PRSs in the PGS Catalog. To evaluate the power of PRS and improve computational efficiency, we employed the theoretic power and variance of partial R^2 for continuous traits and liability R^2 for binary traits (see Methods). We observed that PRSmix+ further improved the prediction accuracy compared to the best PGS Catalog in European ancestry (Fig. 3a) and South Asian ancestry (Fig. 3b). We observed an improvement of 1.70-fold (95% CI: [1.47; 1.93]; P-value = 2.13 x 10^{-9} and 1.42-fold (95% CI: [1.25; 1.59]; P-value = 8.01 x 10^{-7}) higher compared to the best PGS Catalog for European ancestry and South Asian ancestry, respectively. PRSmix+ significantly improved the prediction accuracy compared to PRSmix, in both European and South Asian ancestry with 1.42-fold (95% CI: [1.22; 1.62]; P-value = 2.32 x 10^{-5}) and 1.19-fold (95% CI: [1.07; 1.32]; P-value = 0.001), respectively (Supplementary Fig. 3).

Consistent with our simulation results, a smaller improvement was observed for traits with a higher baseline prediction accuracy from PGS Catalog (Supplementary Fig. 4), noting that the baseline prediction accuracy depends on the heritability and genetic architecture (i.e. polygenicity). In contrast, more improvement was observed for traits with lower heritability, thus lower prediction accuracy, when comparing the single best PRS (Fig. 1c).

Prediction accuracy and predictive improvement across various types of traits

Figure 4. Prediction accuracy and improvement across various types of traits in the European and South Asian ancestry. We classified the traits into 6 main categories for European ancestry in the *All of Us* cohort and 5 categories for South Asian ancestry in the Genes & Health cohort due to the low prevalence of cancer traits in Genes & Health. The prediction accuracies, **(a)** and **(c),** are estimated as partial R^2 and liability R^2 for continuous traits and binary traits, respectively. The relative improvements, **(b)** and **(d)**, are estimated as the fold-ratio between the prediction accuracies of PRSmix and PRSmix+ against the best PGS Catalog. The order on the axis followed the decrease in the prediction accuracy of PRSmix+. The boxplots in **(a)** and **(c)** show the first to the third quartile of prediction accuracies for 47 traits and 32 traits in European and South Asian ancestries, respectively. The whiskers reflect the maximum and minimum values within the 1.5 × interquartile range

289 for each group. The bars in **(b)** and **(d)** represent the mean prediction accuracy across the
290 traits in that group and the whiskers demonstrate 95% confidence intervals. The red dashed
291 line in (b) and (d) represents the ratio equal to 1 as a reference for comparison with the best
292 PGS Catalog score. The asterisk (*) and (**) indicate P-value < 0.05 and P-value < 0.05 /
293 number of traits in each type with a two-tailed paired t-test, respectively.
294
We next compared PRSmix and PRSmix+ with the best PRS estimated from the PGS
Catalog across 6 categories, including anthropometrics, blood counts, cancer,
cardiometabolic, biochemistry, and other conditions (see Methods). PRSmix demonstrates a
higher prediction accuracy across all types of traits in both European and South Asian
ancestries (Fig. 4). We observed a similar trend in the predictive performance of PRSmix+
across different types of traits. In European, the smallest improvement was in
anthropometric traits of 1.20-fold (95% CI: [1.11; 1.28]; P-value = 3.4 x 10^{-6}) and "other
conditions" (including depression, asthma, migraine, current smoker, hypothyroid,
osteoporosis, glaucoma, rheumatoid arthritis, and gout) obtained the highest mean
predictive improvement of 2.08-fold (95% CI: [1.25; 2.89]; P-value = 9.9 x 10^{-3})
(Supplementary Table 4). In South Asian ancestry, the mean predictive improvement was
highest but also with high variance in "other conditions" (including asthma, migraine, current
smoker, and rheumatoid arthritis) type. Biochemistry demonstrated the smallest
improvement of 1.23-fold (95% CI: [1.15; 1.31]; P-value = 5.8 x 10^{-9}).
309
310 **Clinical utility for coronary artery disease**
311
312

313
Figure 5. Comparison of prediction accuracies with PRSmix, PRSmix+ and CAD PRS
from PGS Catalog. PRSmix was computed as a linear combination of CAD PRS and
PRSmix+ was computed as a linear combination of all significant PRS obtained from the
PGS Catalog. The PRSs were evaluated by liability R^2 in the (**a**) European ancestry from the
All of Us cohort and **b)** South Asian ancestry from the Genes & Health cohort. The bars

indicate the mean prediction accuracy and the whiskers show 95% confidence intervals.
CAD, coronary artery disease.
321

322
Figure 6. Net reclassification improvement (NRI) for coronary artery disease with the
addition of polygenic risk scores to the baseline model in European and South Asian
ancestries. The baseline model for risk prediction includes age, sex, total cholesterol, HDL-
C, systolic blood pressure, BMI, type 2 diabetes, and current smoking status. We compared
the integrative models with PGS Catalog, PRSmix, and PRSmix+ in addition to clinical risk
factors versus the baseline model with only factors. The points indicate the mean estimate
for continuous NRI and the whiskers indicate 95% confidence intervals estimated from 500
bootstraps. HDL-C: High-density lipoprotein; BMI: Body mass index. NRI: Net
Reclassification Improvement.
332
333

To evaluate the utility of the proposed methods, we assessed the PRSmix and PRSmix+ for
coronary artery disease (CAD), which is the leading cause of disability and premature death
among adults[19–21]. The single best CAD PRSs (PRS_{CAD}) s from the PGS Catalog in the
training sample was from Koyama S. et al[22]. and Tamlander M. et al.[23] in European and
South Asian ancestries, respectively (Supplementary Fig. 5). Liability R^2 in the testing
sample with Koyama S et al. for European ancestry was 0.019 (95% CI: [0.013; 0.025]; P-
value = 1.87 x 10^{-9}) and with Tamlander M. et al. for South Asian ancestry was 0.006 (95%
CI: [0.003; 0.009]; P-value = 2.39 x 10^{-4}) (Fig. 5).
342
Subsequently, we assessed the clinical utility of the integrative model with PRS and
established clinical risk factors, including age, sex, total cholesterol, HDL-C, systolic blood
pressure, BMI, type 2 diabetes, current smoking status versus the traditional model with
clinical risk factors. (Fig. 6 and Supplementary Table 5). In European ancestry, the CAD
PRSmix+ integrative score improved the continuous net reclassification of 35% (95% CI:
[22%; 48%]; P-value = 7.08 x 10^{-8}) compared to PRSmix (30%; 95% CI: [18%; 42%]; P-value
= 9.11 x 10^{-7}) and the best PRS from the PGS Catalog (19%; 95% CI: [5%; 33%]; P-value =

0.007). In South Asian ancestry, the integrated score with PRSmix+ showed significant continuous net reclassification of 27% (95% CI: [16%; 38%]; P-value = 6.07 x 10^{-7}) compared to PRSmix (15%; 95% CI: [9%; 20%]; P-value = 7.18 x 10^{-6}) and the best PGS Catalog (7%; 95% CI: [1%; 13%]; P-value = 0.02). Our results also demonstrated an improvement in net reclassification for models without clinical risk factors (Supplementary Table 5).

We assessed the incremental area under the curve (AUC) between the full model of PRS and covariates and the null model with only covariates (Supplementary Table 6). PRSmix+ demonstrated an incremental AUC of 0.02 (95% CI: [0.018; 0.02]; P-value < 2.2×10^{-16}) and 0.008 (95% CI: [0.007; 0.009]; P-value<2.2×10^{-16}) in European and South Asian ancestries, respectively. PRSmix obtained an incremental AUC of 0.013 (95% CI: [0.013; 0.014]; P-value < 2.2×10^{-16}) and 0.006 (95% CI: [0.005; 0.007]; P-value < 2.2×10^{-16}) in European and South Asian ancestries, respectively. The best PGS Catalog had the smallest incremental AUC of 0.007 (95% CI: [0.007; 0.008]; P-value<2.2×10^{-16}) and 0.003 (95% CI: [0.002; 0.003]; P-value < 2.2×10^{-16}) in European and South Asian ancestries, respectively.

We also compared the risks for individuals in the top decile versus the remaining population (Supplementary Table 7). For European ancestry, an increased risk with OR per 1-SD of the best PGS Catalog, PRSmix and PRSmix+ were 1.39 (95% CI: [1.27-1.52]; P-value < 1.52 x 10^{-16}), 1.52 (95% CI: [1.39-1.67]; P-value < 2.2×10^{-16}) and 1.66 (95% CI = [1.51; 1.82]; P-value < 2.2×10^{-16}), respectively. The top decile of PRSmix+ compared to the remaining population demonstrated an increased risk of OR = 2.54 (95% CI: [1.97; 3.25]; P-value = 3.91 x 10^{-13}). The top decile for the best PGS Catalog versus the remainder was OR = 2.14 (95% CI: [1.66; 2.74]; P-value = 2.27 x 10^{-9}). For South Asian ancestry, an increased risk with OR per 1-SD of the best PGS Catalog, PRSmix and PRSmix+ was 1.24 (95% CI: [1.13; 1.37]; P-value < 1.52×10^{-16}), 1.39 (95% CI: [1.33; 1.46]; P-value < 2.2 x 10^{-16}), 1.40 (95% CI: [1.27; 1.55]; P-value < 2.2×10^{-16}) and 1.50 (95% CI = [1.36; 1.66]; P-value < 2.2×10^{-16}), respectively. In South Asian ancestry, PRSmix+ demonstrated an OR of 2.34 (95% CI: [1.79; 3.05]; P-value = 4.22 x 10^{-10}), and with the best PGS Catalog, OR was 1.73 (95% CI: [1.30; 2.28]; P-value = 1.31 x 10^{-4}) for the top decile versus the remaining population.

Moreover, we observed that there is a plateau of improvement for PRSmix from the training size of 5000 in both European and South Asian ancestries (Supplementary Fig. 6), which aligned with our simulations (Fig. 2a and 2b). Our results demonstrated the generalization of our combination methods across diverse ancestries to improve prediction accuracy. With PRSmix+, our empirical result showed that there was a modest improvement with training sample sizes larger than 5,000.

Finally, we conducted phenome-wide association studies (PheWAS) in *All of Us* between PRS_{CAD} with 1815 phecodes to compare the pleiotropy of PRS and assess the relationship between CAD PRS and disease phenotypes given the inherent use of pleiotropy in development (Supplementary Table 8). As expected, PRSmix+ had a stronger association for ischemic heart disease relative to the single best PRS from the PGS Catalog. Despite extensive use of pleiotropy in performance, PRSmix+ associations with cardiometabolic risk factors were only mildly greater in risk increase (Supplementary Table 8). The PheWAS result for PRSmix+ aligned with the list of traits from the selected PRS (Supplementary Fig. 7, and Supplementary Table 8)

DISCUSSION

In this paper, we propose a trait-specific framework (PRSmix), and cross-trait framework
(PRSmix+) to leverage the combined power of existing scores. We performed and evaluated
our method using the *All of Us* and Genes & Health cohorts showcasing a framework to
develop the most optimal PRS for a given trait in a target population leveraging all existing
PRS. Across 47 traits in All of Us cohort and 32 traits in the Genes & Health cohort with
either continuous traits or binary traits with prevalence > 2%, we demonstrated substantial
improvement in average prediction R^2 by using a linear combination with Elastic Net. The
empiric observations are concordant with simulations. To our knowledge, there has been a
number of emerging studies to combine PRS, but there is a limited number of frameworks
that comprehensively evaluate, harmonize, and leverage the combination of these
scores[8,13,24]. Our studies permit several conclusions for the development, implementation,
and transferability of PRS.

First, externally derived and validated PRS are generally not the most optimal PRS for a
given cohort. Consistent with other risk predictors, recalibration within the ultimate target
population improves performance[25]. By leveraging the PGS Catalog, our work carefully
harmonizes the risk alleles to estimate PRS across all scores and provides newly estimated
per-allele SNP effects (provided to the PGS Catalog) to assist the interpretability of the
models.

Second, previous studies selected an arbitrary training sample size to estimate the mixing
weights, which may lead to a poor power of the combination frameworks and inaccurate
estimate of sampling variance[10]. We assessed the expected sample sizes to estimate the
mixing weights via simulations and real data. Our results demonstrated that while low
heritability traits benefit the most, they require a greater training sample size.

Third, we leveraged all PRS, including those not trained on the primary trait, to
systematically optimize PRS for a target cohort. We showed that PRSmix improved the
prediction by combining the scores matching the outcome trait. In addition, we showed that
PRSmix+ was able to leverage the power of cross-traits, which highlighted the contribution
of pleiotropic effects to enhance PRS performance. We leverage prior work demonstrating
the effects of pleiotropy on complex traits[15,26,27]. It is noted that our proposed framework is
related to the metaPRS approach advanced by Abraham et al. for stroke, however, selected
with prior knowledge[8]. Our framework utilizes all PRSs available in the PGS Catalog.
Additional summary statistics could be added to further enhance the models. We let our
model penalize the high-power PRS without the need for prior knowledge. We also observed
that our method could identify more related risk factors to include compared to previous work
conducted on stroke (Supplementary Fig. 8). Therefore, our method is more comprehensive
in an unbiased way in terms of choosing the risk factors and traits to include with empirically
improved performance.

Fourth, greater performance is observed even for non-European ancestry groups
underrepresented in GWAS and PRS studies. We empirically demonstrate the value of
training and incorporating pleiotropy with all available PRS to improve performance,
including multiple metrics of clinical utility for CAD prediction in multiple ancestries. In South

Asian ancestry, we observed that PRSmix and PRSmix+ demonstrated a significant
improvement with the best improvement for CAD. Of note for CAD, the relative
improvements in South Asian ancestry were higher than in European ancestry for PRSmix
and equivalent for PRSmix+. Transferability of PRS has been shown to improve the clinical
utility of PRS in non-European ancestry[16,28]. Although the prediction accuracy for South
Asian ancestry is still limited, our results highlighted the transferability of predictive
improvement with PRSmix and PRSmix+ to South Asian ancestry. We anticipate that
ongoing and future efforts to improve our understanding of the genetic architecture in non-
European ancestries will further improve the transferability of PRS across ancestry.
455
Lastly, traits with low heritability or generally low-performing single PRS benefit the most
from this approach, especially with PRSmix+, such as migraine in both European and South
Asian ancestries. Additionally, our results showed that pleiotropic effects play an important
role in understanding and improving prediction accuracies of complex traits. However,
anthropometric traits, which are highly polygenic[29] and have good predictive performance
using the best PGS Catalog, also showed improvement with the combination framework in
both European and South Asian ancestries.
463
Given that PRSmix+ outperformed PRSmix, one might consider if there is a reason to use
PRSmix instead of PRSmix+. We observed that in cases of highly heritable traits or high
performance with a single PRS, there was only marginal improvement of PRSmix+ over
PRSmix. In this scenario, PRSmix could provide similar predictive performance while being
less time-consuming because trait-specific PRS inputs only are required. However, for traits
with lower heritability PRSmix+ shows a marked improvement over PRSmix and would be
preferred. Wang et al.[30] showed that the theoretical prediction accuracy of the target trait
using the PRS from the correlated trait is a function of genetic correlation, heritability,
number of genetic variants and sample size. Future directions could include defining the
minimum parameters required for the performance of the PRSmix+ model to improve on
single trait-specific PRS.
475
Our work has several limitations. First, the majority of scores from PGS Catalog were
developed in European ancestry populations. Further non-European SNP effects will likely
improve the single PRS power, which may in turn, also improve the prediction accuracy of
our proposed methods. Second, the Elastic Net makes a strong assumption that the
outcome trait depends on a linear association with the PRS and covariates. However, a
recent study demonstrated there is no statistical significance difference between linear and
non-linear combinations for neuropsychiatric disease[13]. Third, we did not validate the mixing
weights in an independent cohort. We expect that in the future, there will be emerging large
independent biobanks, but prior non-genetic work demonstrates the value of internal
calibration for optimal risk prediction. Fourth, we estimated the mixing weights for each
single SNP as a mixing weight of the PRS. Future studies could consider linkage
disequilibrium between the SNPs and functional annotations of each SNP. Fifth, our
frameworks were conducted on binary traits with a prevalence > 2%. Additional combination
PRS models are emerging that seek to use preexisting genotypic data from genetically
related, but low prevalence conditions, to improve the prediction accuracy of rare
conditions[13]. Sixth, the baseline demographic characteristics (i.e., age, sex, social economic
status) in the target cohort might limit the validation and transferability of PRS[31]. Although
these factors were considered by using a subset of the target cohorts as training data, it is

necessary to have PRS developed on similar baseline characteristics. Lastly, with the
expanding of all biobanks, there might be no perfect distinction between the samples
deriving PRS and the testing cohort, future studies may consider the potential intersection
samples to train the linear combination.
498
499   In conclusion, our framework demonstrates that leveraging different PRS either trait-specific
500   or cross-trait can substantially improve model stability and prediction accuracy beyond all
501   existing PRS for a target population. Importantly, we provide software to achieve this goal in
502   independent cohorts.
503
504   **METHODS**
505
506   **Data**
507
508   *The All of Us Research Program*
509
The *All of Us* Research Program is a longitudinal cohort continuously enrolling (starting May
2017) U.S. adults ages 18 years and older from across the United States, with an emphasis
on promoting inclusion of diverse populations traditionally underrepresented in biomedical
research, including gender and sexual minorities, racial and ethnic minorities, and
participants with low levels of income and educational attainment.[32] Participants in the
program can opt-in to providing self-reported data, linking electronic health record data, and
providing physical measurement and biospecimen data.[33] Details about the *All of Us* study
goals and protocols, including survey instrument development,[34] participant recruitment, data
collection, and data linkage and curation were previously described in detail.[33,35]
519
Data can be accessed through the secure *All of Us* Researcher Workbench platform, which
is a cloud-based analytic platform that was built on the Terra platform.[36] Researchers gain
access to the platform after they complete a 3-step process including registration,
completion of ethics training, and attesting to a data use agreement attestation.[37] *All of Us*
uses a tiered approach based on what genomic data is accessible through the Controlled
Tier, and includes both whole genome sequencing (WGS), genotyping array variant data in
multiple formats, as well as variant annotations, access to computed ancestry, and quality
reports.[38] This study includes data on the 98,600 participants with (WGS) data in the *All of
Us* v5 Curated Data Repository release. Participant data in this data release was collected
between May 6, 2018 and April 1, 2021. This project is registered in the *All of Us* program
under the workspace name "Polygenic risk score across diverse ancestries and biobanks."
531
532   *The Genes & Health Biobank*
533
Genes & Health is a community-based genetics study enrolling British South Asian, with an
emphasis on British Bangladeshi (two-thirds) and British Pakistani (remaining) people, with a
goal of recruiting at least 100,000 participants. Currently, over 52,000 participants have
enrolled since 2015. All participants have consented for lifelong electronic health record
access and genetic analysis. The study was approved by the London South East National
Research Ethics Service Committee of the Health Research Authority. 97.4% of participants
in Genes & Health are in the lowest two quintiles of the Index of Multiple Deprivation in the
United Kingdom. The cohort is broadly representative of the background population with

regard to age, but slightly over-sampled with females and those with medical problems since
two-thirds of people were recruited in healthcare settings such as General Practitioner
surgeries[39].
545
546 *The Polygenic Score (PGS) Catalog*
547
Polygenic risk scores were obtained from the Polygenic Score (PGS) Catalog[17], which is a
publicly accessible resource cataloging published PRS, including the metadata. The
metadata provides information describing the computational algorithms used to generate the
score, and performance metrics to evaluate a PRS[17]. At the time of this study, over 2,600
PRS were cataloged in the PGS Catalog (version July 18, 2022) designed to predict 538
distinct traits.
554
555 **Clinical Outcomes**
556
Clinical phenotypes were curated using a combination of electronic health record data, direct
physical measurements, and/or self-reported personal medical history data, from the *All of*
Us v5 Data Release as detailed in Supplementary Table 13. Individuals in the Genes and
Health cohort were also curated with similar definitions based on ICD10, SNOMED and
operation codes (Supplementary Table 14). Traits with the best performing single trait-
specific PRS with power < 0.95 such as hemoglobin, sleep apnea, and depression were
removed. Binary traits with a prevalence < 2% were removed.
564
565 **A linear combination of scores**
566
We proposed PRSmix to combine PRS of outcome traits and PRSmix+ to combine high-
power PRS (defined in the following subsection) from all traits obtained from PGS Catalog.
The linear combination was conducted by using an Elastic Net algorithm from the "glmnet" R
package (version 4.1) to combine the estimated PRS. First, we randomly split the
independent cohorts into 80% of training and 20% testing. The PRS in the training set was
standardized with mean 0 and variance 1. Before conducting linear combination, we first
evaluated the performance of each individual PRS by their power and P-value (see below).
An Elastic Net algorithm was used with 5-fold cross-validation and default parameters to
estimate the mixing weights of each PRS. The mixing weights were then divided by the
corresponding original standard deviation of the PRS in the training set.
577

$$\hat{\alpha}_i = \hat{\omega}_i \: / \: \sigma_i$$

578
579 Where $\hat{\omega}_i$ and σ_i is the mixing weight estimated from the Elastic Net and standard deviation
580 of PRS$_i$ in the training set, respectively. $\hat{\alpha}_i$ is the adjusted mixing weight for PRS$_i$. To derive
581 the per-allele effect sizes from the combination framework, we multiplied the SNP effects
582 with the corresponding adjusted mixing weights:

$$\hat{\gamma}_j = \sum_{i=1}^{M} \hat{\alpha}_i * \beta_{ji}$$

583 Where $\hat{\gamma}_j$ is the adjusted effect size of SNP$_j$ and β_{ij} is the original effect sizes of SNP$_j$ in
584 PRS$_i$. We set $\beta_{ji} = 0$ if SNP$_j$ is not in PRS$_i$. The adjusted effect sizes were then utilized to
585 calculate the final PRS.

586
587 The mixing weights for PGS Catalog scores for PRSmix and PRSmix+ in European ancestry
588 are provided in Supplementary Table 9 and Supplementary Table 10, respectively. For
589 South Asian ancestry, the mixing weights for PRSmix and PRSmix+ in European ancestry
590 are provided in Supplementary Table 11 and Supplementary Table 12, respectively.
591

Power and variance of PRS accuracy

593
We selected high-power PRS to conduct the combination by assessing the power and
variance of prediction accuracy. The power of PRS can be estimated based on the power of
the two-tailed test of association as follow[3,40]:

$$1 - \phi(\phi^{-1}(1 - \alpha/2) - \sqrt{\lambda}) + \phi(\phi^{-1}(\alpha/2) - \sqrt{\lambda}) \quad (1)$$

where ϕ is the Chi-squared distribution function, α is the significance level, and λ is the non-
centrality parameter which can be estimated as

$$\lambda = \frac{NR^2}{1 - R^2} \quad (2)$$

where N, R^2 is the sample size and estimated prediction accuracy in the testing set,
respectively. R^2 can be estimated as partial R^2 or liability R^2 for continuous traits and binary
traits, respectively. Briefly, partial R^2 compared the difference in goodness-of-fit between a
full model with PRS and covariates including age, sex, and first 10 PCs, and a null model
with only covariates. Additionally, for binary traits, liability R^2 was estimated with the disease
prevalence approximated as the prevalence in the samples. The theoretical variance and
standard error of R^2 can be estimated as follow[41–43]:

$$se(R^2) = \sqrt{var(R^2)} = \sqrt{\frac{4R^2(1-R^2)(N-2)^2}{(N^2-1)(N+3)}} \quad (3)$$

Therefore, we can analytically estimate the confidence interval of prediction accuracy for
each of the score. We selected high-power scores defined as power > 0.95 with P-value <=
0.05 or P-value <= 1.9 x 10^{-5} (0.05/2600) for the combination with Elastic Net.

To compare the improvement, for instance between PRSmix and the best PGS Catalog, we
estimate the mean fold-ratio of R^2 across different traits with its 95% confidence interval and
evaluated the significance difference from 1 using a two-tailed paired t-test.
622

Simulations

624
We used UK Biobank European ancestry to conduct simulations for trait-specific and cross-
trait combinations. Overall, we simulated 7 traits with heritability h^2 equal to 0.05, 0.1, 0.2,
and 0.5. We randomly selected M=1000 causal SNPs among 1.1 million HapMap3 variants
with INFO > 0.6, MAF > 0.01 and P-value Hardy-Weinberg equilibrium > 10^{-7}. We removed
individuals with PC1 and PC2 > 3 standard deviation from the mean. We randomly remove
one in a pair of related individuals with closer than 2nd degree. The genetic components
were simulated as PRSs where PRS1, PRS2, and PRS3 are considered trait-specific scores

with genetic correlations are 0.8 and 0.4 for cross-trait scores. PRS4, PRS5 and PRS6 are
simulated as pleiotropic effects on the outcome traits with genetic correlation equal to 0.4.
The SNP effects for PRSs are simulated by a multivariate normal distribution MVN(0, Σ)
where Σ is the covariance matrix between PRSs. The main diagonal contains the heritability
of the traits as h^2 / M and the covariance between PRSs are simulated as $r_g * h^2 / M$ where
r_g is the genetic correlation between PRSs (0.8 for trait-specific scores and 0.4 for cross-trait
scores). The PRSs of the outcome are estimated by the weighted combination of PRS where
the weights follow U(0,1). 7 phenotypes were simulated as $y = g + e, e \sim N(0, 1 - h^2)$ where
g is PRS and e is the residuals.
641
We split the simulated cohort into 3 data sets for: 1) GWAS 2) training set: training the
mixing weights with a linear combination and 3) testing set: testing the combined PRS. We
incorporated PRS1, PRS2 and PRS3 to assess the trait-specific PRSmix framework. We
combined all 6 single PRS to evaluate the cross-trait PRSmix+ framework. We compared
the fold-ratio of the R^2 of the combined PRS to the R^2 of best single PRS to assess the
improvement of the combination strategy. To evaluate the improvement across different
heritabilities, we estimated the slope of improvement per log10(N) increase of training
sample sizes on the fold-ratio of predictive improvement.
650
651   **Sample and genotyping quality control**
652
The AoU data version 5 contains more than 700 million variants from whole genome
sequencing[33]. We curated European ancestry by predicted genetic ancestry with a
probability > 90% provided by AoU yielding 48,351 individuals in the AoU. For variant quality
control beyond AoU central efforts, we further filtered SNPs to include MAF > 0.001 which
retained 9,538,437 SNPs. We performed a similar quality control for imputed genotype data
for South Asian ancestry in the Genes & Health cohort with additional criteria of INFO score
> 0.6 and genotype missing rate < 5%. Individuals with a missing rate > 5% were removed.
Eventually, 44,396 individuals and 8,935,207 SNPs remained in Genes & Health.
661
662   **Assessment of clinical utility**
663
We applied PRSmix and PRSmix+ for coronary artery disease as a clinical application. The
phenotypic algorithm includes at least one ICD or CPT code below: ICD9 410x, 411x, 412x;
ICD10 I22x, I23x, I24.1, I25.2 CPT 92920-92979 (PCI), 33533-33536, 33517-33523, 33510-
33516 (CABG) or self-reported personal history of MI or CAD. CAD in Genes and Health
cohort was defined with at least one ICD10 I22x, I23x, I24.1, I25 or operation codes K401,
K402, K403, K404, K411, K451, K452, K453, K454, K455, K491, K492, K499, K502, K751,
K752, K753, K754, K758, K759 or SNOMED codes 1755008, 22298006, 54329005,
57054005, 65547006, 70211005, 70422006, 73795002, 233838001, 304914007,
401303003, 401314000.
673
674   The category-free NRI was used to evaluate the clinical utility. NRI was calculated by adding
675   the PRS to the baseline logistic model including age, sex, the first 10 principal components,
676   and clinical risk factors. The clinical risk factors include total cholesterol, HDL-C, BMI, type 2
677   diabetes, and current smoking status or model includes only age, sex, and 10 principal
678   components. NRI was calculated as the sum of NRI for cases and NRI for controls:

$$NRI = P(up|case) - P(down|case) + P(down|control) - P(up|control)$$

$P(up|case)$ and $P(down|case)$ estimate the proportion of cases that had higher or lower risk
after classification with logistic regression, respectively. The confidence interval for NRI was
estimated with 500 bootstraps. We also compared the risk increase between individuals in
the top decile of PRS versus those remaining in the population. In addition to liability R^2 to
compare the PRS performance, we also used the incremental area under the curve (AUC) to
compare the PRS. The incremental AUC was estimated as the difference between the AUC
of models with the integrative score versus the model with only clinical variables.

Phenome-wide association study

We obtained the list of 1815 phecodes from the PheWAS website (last accessed December
2022)[44]. The phecodes were based on ICD-9 and ICD-10 to classify individuals. PheWAS
was conducted on European ancestry only in AoU. For each phecodes as the outcome, we
conducted an association analysis using logistic regression on PRS and adjusted for age,
sex, and first 10 PCs. The significance threshold for PheWAS was estimated as 2.75×10^{-5}
(0.05/1815) after Bonferroni correction.

Data availability

The PGS Catalog is freely available at https://www.pgscatalog.org/. Our new scores are
deposited in the PGS Catalog. The All of Us and Genes & Health individual-level data is a
controlled access dataset and may be granted at https://www.researchallofus.org/ and
https://www.genesandhealth.org/, respectively.

The weights from the PRSmix and PRSmix+ scores in this manuscript have been returned to
the PGS Catalog. The R package to implement PRSmix and PRSmix+ in independent
datasets is at https://github.com/buutrg/PRSmix.

Software/analyses:
Analyses were performed on the AoU Researcher Workbench in Jupyter Notebook 14 using
R version 4.0.0 programming language. Results are reported in compliance with the AoU
Data and Statistics Dissemination Policy.

ACKNOWLEDGEMENT

We would like to thank Alkes L. Price for critical comments for this works. L.E.H. is
supported by the National Human Genome Research Institute (K08HG012221). P.N. is
supported by grants from NHGRI (U01HG011719), NHLBI (R01HL142711, R01HL127564,
R01HL151152), and Massachusetts General Hospital (Paul & Phyllis Fireman Endowed
Chair in Vascular Medicine). The content is solely the responsibility of the authors and does
not necessarily represent the official views of the National Institutes of Health.

The *All of Us* Research Program is supported by the National Institutes of Health, Office of
the Director: Regional Medical Centers: 1 OT2 OD026549; 1 OT2 OD026554; 1 OT2
OD026557; 1 OT2 OD026556; 1 OT2 OD026550; 1 OT2 OD 026552; 1 OT2 OD026553; 1

OT2 OD026548; 1 OT2 OD026551; 1 OT2 OD026555; IAA #: AOD 16037; Federally
Qualified Health Centers: HHSN 263201600085U; Data and Research Center: 5 U2C
OD023196; Biobank: 1 U24 OD023121; The Participant Center: U24 OD023176; Participant
Technology Systems Center: 1 U24 OD023163; Communications and Engagement: 3 OT2
OD023205; 3 OT2 OD023206; and Community Partners: 1 OT2 OD025277; 3 OT2
OD025315; 1 OT2 OD025337; 1 OT2 OD025276. In addition, the All of Us Research
Program would not be possible without the partnership of its participants.
733
Genes & Health is/has recently been core-funded by Wellcome (WT102627, WT210561),
the Medical Research Council (UK) (M009017), Higher Education Funding Council for
England Catalyst, Barts Charity (845/1796), Health Data Research UK (for London
substantive site), and research delivery support from the NHS National Institute for Health
Research Clinical Research Network (North Thames). Genes & Health is/has recently been
funded by Alnylam Pharmaceuticals, Genomics PLC; and a Life Sciences Industry
Consortium of Bristol-Myers Squibb Company, GlaxoSmithKline Research and Development
Limited, Maze Therapeutics Inc, Merck Sharp & Dohme LLC, Novo Nordisk A/S, Pfizer Inc,
Takeda Development Centre Americas Inc.
743
We thank Social Action for Health, Centre of The Cell, members of our Community Advisory
Group, and staff who have recruited and collected data from volunteers. We thank the NIHR
National Biosample Centre (UK Biocentre), the Social Genetic & Developmental Psychiatry
Centre (King's College London), Wellcome Sanger Institute, and Broad Institute for sample
processing, genotyping, sequencing and variant annotation. We thank: Barts Health NHS
Trust, NHS Clinical Commissioning Groups (City and Hackney, Waltham Forest, Tower
Hamlets, Newham, Redbridge, Havering, Barking and Dagenham), East London NHS
Foundation Trust, Bradford Teaching Hospitals NHS Foundation Trust, Public Health
England (especially David Wyllie), Discovery Data Service/Endeavour Health Charitable
Trust (especially David Stables), NHS Digital - for GDPR-compliant data sharing backed by
individual written informed consent.
755
756   Most of all we thank all of the volunteers participating in the *All of Us* Research Program and
757   Genes & Health.

758
759   **CONFLICT OF INTEREST**
760
P.N. reports grants from Allelica, Amgen, Apple, Boston Scientific, Genentech, and Novartis,
is a consultant to Allelica, Apple, AstraZeneca, Blackstone Life Sciences, Foresite Labs,
HeartFlow, Novartis, Genentech, and GV, scientific advisory board membership to Esperion
Therapeutics, Preciseli, and TenSixteen Bio, is a scientific co-founder of TenSixteen Bio,
and spousal employment at Vertex Pharmaceuticals, all unrelated to the present work.
Others declare no conflict of interest.
767
768

REFERENCES

1. Catalog, P. G. S. PGS Catalog - the Polygenic Score Catalog.
   http://www.pgscatalog.org/.

2. Choi, S. W., Mak, T. S.-H. & O'Reilly, P. F. Tutorial: a guide to performing polygenic risk
   score analyses. *Nat. Protoc.* **15**, 2759–2772 (2020).

3. Dudbridge, F. Power and predictive accuracy of polygenic risk scores. *PLoS Genet.* **9**,
   e1003348 (2013).

4. Choi, S. W. & O'Reilly, P. SA20 - PRSice 2: POLYGENIC RISK SCORE SOFTWARE
   (UPDATED) AND ITS APPLICATION TO CROSS-TRAIT ANALYSES. *Eur.*
   Neuropsychopharmacol. **29**, S832 (2019).

5. Privé, F., Arbel, J. & Vilhjálmsson, B. J. LDpred2: better, faster, stronger. *Bioinformatics*
   (2020) doi:10.1093/bioinformatics/btaa1029.

6. Vilhjálmsson, B. J. *et al.* Modeling Linkage Disequilibrium Increases Accuracy of
   Polygenic Risk Scores. *Am. J. Hum. Genet.* **97**, 576–592 (2015).

7. Ge, T., Chen, C.-Y., Ni, Y., Feng, Y.-C. A. & Smoller, J. W. Polygenic prediction via
   Bayesian regression and continuous shrinkage priors. *Nat. Commun.* **10**, 1776 (2019).

8. Abraham, G. *et al.* Genomic risk score offers predictive performance comparable to
   clinical risk factors for ischaemic stroke. *Nat. Commun.* **10**, 5819 (2019).

9. Chung, W. *et al.* Efficient cross-trait penalized regression increases prediction accuracy
   in large cohorts using secondary phenotypes. *Nat. Commun.* **10**, 569 (2019).

10. Weissbrod, O. *et al.* Leveraging fine-mapping and multipopulation training data to
    improve cross-population polygenic risk scores. *Nat. Genet.* **54**, 450–458 (2022).

11. Inouye, M. *et al.* Genomic Risk Prediction of Coronary Artery Disease in 480,000 Adults:
    Implications for Primary Prevention. *J. Am. Coll. Cardiol.* **72**, 1883–1893 (2018).

12. Ruan, Y. *et al.* Improving polygenic prediction in ancestrally diverse populations. *Nat.*
    Genet. **54**, 573–580 (2022).

13. Albiñana, C. *et al.* Multi-PGS enhances polygenic prediction: weighting 937 polygenic
    scores. Preprint at https://doi.org/10.1101/2022.09.14.22279940.

14. Watanabe, K. *et al.* A global overview of pleiotropy and genetic architecture in complex

traits. *Nat. Genet.* **51**, 1339–1348 (2019).

15. Li, C., Yang, C., Gelernter, J. & Zhao, H. Improving genetic risk prediction by leveraging

pleiotropy. *Hum. Genet.* **133**, 639–650 (2014).

16. Martin, A. R. *et al.* Clinical use of current polygenic risk scores may exacerbate health

disparities. *Nature Genetics* vol. 51 584–591 Preprint at https://doi.org/10.1038/s41588-

019-0379-x (2019).

17. Lambert, S. A. *et al.* The Polygenic Score Catalog as an open database for

reproducibility and systematic evaluation. *Nat. Genet.* **53**, 420–425 (2021).

18. Buch, G., Schulz, A., Schmidtmann, I., Strauch, K. & Wild, P. S. A systematic review

and evaluation of statistical methods for group variable selection. *Stat. Med.* **42**, 331–

352 (2023).

19. Klarin, D. & Natarajan, P. Clinical utility of polygenic risk scores for coronary artery

disease. *Nat. Rev. Cardiol.* **19**, 291–301 (2022).

20. Heart Association Council on Epidemiology, A. Heart disease and stroke statistics—

2022 update: a report from the American Heart Association. *Circulation* (2022).

21. Arnett, D. K. *et al.* 2019 ACC/AHA Guideline on the Primary Prevention of

Cardiovascular Disease: A Report of the American College of Cardiology/American

Heart Association Task Force on Clinical Practice Guidelines. *Circulation* **140**, e596–

e646 (2019).

22. Koyama, S. *et al.* Population-specific and trans-ancestry genome-wide analyses identify

distinct and shared genetic risk loci for coronary artery disease. *Nat. Genet.* **52**, 1169–

1177 (2020).

23. Tamlander, M. *et al.* Integration of questionnaire-based risk factors improves polygenic

risk scores for human coronary heart disease and type 2 diabetes. *Commun Biol* **5**, 158

(2022).

24. Zhang, H. *et al.* Novel methods for multi-ancestry polygenic prediction and their

evaluations in 5.1 million individuals of diverse ancestry. *bioRxiv* (2022)

doi:10.1101/2022.03.24.485519.

25. Sud, M. *et al.* Population-Based Recalibration of the Framingham Risk Score and

Pooled Cohort Equations. *J. Am. Coll. Cardiol.* **80**, 1330–1342 (2022).

26. Carroll, R. J., Bastarache, L. & Denny, J. C. R PheWAS: data analysis and plotting tools

for phenome-wide association studies in the R environment. *Bioinformatics* **30**, 2375–

2376 (2014).

27. Bastarache, L., Denny, J. C. & Roden, D. M. Phenome-Wide Association Studies. *JAMA*

327, 75–76 (2022).

28. Wang, M. *et al.* Validation of a Genome-Wide Polygenic Score for Coronary Artery

Disease in South Asians. *J. Am. Coll. Cardiol.* **76**, 703–714 (2020).

29. Lloyd-Jones, L. R. *et al.* Improved polygenic prediction by Bayesian multiple regression

on summary statistics. *Nat. Commun.* **10**, 5086 (2019).

30. Wang, Y., Tsuo, K., Kanai, M., Neale, B. M. & Martin, A. R. Challenges and

opportunities for developing more generalizable polygenic risk scores. *Annu. Rev.*

Biomed. Data Sci. **5**, 293–320 (2022).

31. Mostafavi, H. *et al.* Variable prediction accuracy of polygenic scores within an ancestry

group. *Elife* **9**, (2020).

32. Mapes, B. M. *et al.* Diversity and inclusion for the All of Us research program: A scoping

review. *PLoS One* **15**, e0234962 (2020).

33. The "All of Us" Research Program. *N. Engl. J. Med.* **381**, 668–676 (2019).

34. Cronin, R. M. *et al.* Development of the initial surveys for the All of Us Research

Program. *Epidemiology* **30**, 597–608 (2019).

35. All of Us Research Program Protocol. *All of Us Research Program | NIH*

https://allofus.nih.gov/about/all-us-research-program-protocol (2020).

36. Pereira, F. Home. *Terra.Bio* https://terra.bio/ (2020).

37. Researcher Workbench. https://www.researchallofus.org/workbench/.

38. Data Methods – All of Us Research Hub. https://www.researchallofus.org/data-

tools/methods.

39. Finer, S. *et al.* Cohort Profile: East London Genes & Health (ELGH), a community-
based population genomics and health study in British Bangladeshi and British Pakistani
people. *International Journal of Epidemiology* vol. 49 20–21i Preprint at
https://doi.org/10.1093/ije/dyz174 (2020).

40. Lee, S. H., Clark, S. & van der Werf, J. H. J. Estimation of genomic prediction accuracy
from reference populations with varying degrees of relationship. *PLoS One* **12**,
e0189775 (2017).

41. Wishart, J., Kondo, T. & Elderton, E. M. The mean and second moment coefficient of
the multiple correlation coefficient, in samples from a normal population. *Biometrika* **22**,
353 (1931).

42. Stuart, A., Ord, K. & Arnold, S. *Kendall's Advanced Theory of Statistics, Classical
Inference and the Linear Model*. (Wiley, 2010).

43. Momin, M. M., Lee, S., Wray, N. R. & Lee, S. H. Significance tests for R2 of out-of-
sample prediction using polygenic scores. *Am. J. Hum. Genet.* (2023)
doi:10.1016/j.ajhg.2023.01.004.

44. Denny, J. C. *et al.* PheWAS: demonstrating the feasibility of a phenome-wide scan to
discover gene-disease associations. *Bioinformatics* **26**, 1205–1210 (2010).